MedTrace Logo

A Phase 3 Substudy to Evaluate Executive Function in Adults With PKU Who Are Participating in the Phase 3 Study, 165-302

NCT02468570 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 9

Last updated 2020-06-04

Study results available
· View outcomes & findings →

Summary

A Phase 3 substudy to evaluate executive function in adults with phenylketonuria who are participating in the phase 3 Study, 165-302. Approximately 100 subjects, aged ≥ 18 to ≤ 70 years old, with PKU will be enrolled.

Conditions

Interventions

OTHER

Administration of CANTAB and Subject Global Assessment

At designated visits, subject will perform the CANTAB tasks and complete the Subject Global Assessment Questionnaire

Sponsors & Collaborators

Principal Investigators

  • Debra Lounsbury · Principal Scientist/Medical Monitor

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-05
Primary Completion
2017-02-01
Completion
2017-02-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02468570 on ClinicalTrials.gov